Loxo Oncology Inc. (NASDAQ:LOXO)’s share price shot up 2.8% during trading on Wednesday . The company traded as high as $26.89 and last traded at $26.51, with a volume of 53,954 shares traded. The stock had previously closed at $25.79.

A number of brokerages have commented on LOXO. Zacks Investment Research downgraded shares of Loxo Oncology from a “buy” rating to a “hold” rating in a research note on Saturday, August 6th. Cowen and Company reaffirmed a “buy” rating on shares of Loxo Oncology in a research note on Wednesday, July 13th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $29.60.

The stock’s 50 day moving average price is $25.76 and its 200-day moving average price is $23.93. The company’s market cap is $579.08 million.

Loxo Oncology (NASDAQ:LOXO) last issued its earnings results on Wednesday, August 3rd. The biopharmaceutical company reported ($0.77) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.63) by $0.14. On average, analysts anticipate that Loxo Oncology Inc. will post ($2.83) earnings per share for the current fiscal year.

In other Loxo Oncology news, Director David P. Bonita sold 447,857 shares of the company’s stock in a transaction dated Wednesday, August 10th. The shares were sold at an average price of $26.96, for a total value of $12,074,224.72. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Keith T. Flaherty sold 15,000 shares of the company’s stock in a transaction dated Thursday, August 11th. The stock was sold at an average price of $26.00, for a total transaction of $390,000.00. Following the completion of the transaction, the director now owns 60,482 shares in the company, valued at $1,572,532. The disclosure for this sale can be found here.

Loxo Oncology, Inc is a United States-based biopharmaceutical company. The Company is engaged in developing selective medicines for patients with genetically defined cancers. Its pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.